SCHEMBL584320

SCHEMBL584320

OCCCc1cc(F)c(Cl)c(F)c1

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TNKS2 Q9H2K2 1/20 0.39
FFAR4 Q5NUL3 2/20 0.39
CA2 P00918 2/20 0.35
CYP11B1 P15538 2/20 0.33
CYP11B2 P19099 2/20 0.33
TBXA2R P21731 1/20 0.33
CYP4A11 Q02928 2/20 0.32
TLR8 Q9NR97 2/20 0.31
LTA4H P09960 1/20 0.31
EPHX2 P34913 1/20 0.31
PRKAB2 O43741 1/20 0.31
PRKAG1 P54619 1/20 0.31
PRKAA2 P54646 1/20 0.31
PRKAA1 Q13131 1/20 0.31
PRKAG3 Q9UGI9 1/20 0.31
PRKAG2 Q9UGJ0 1/20 0.31
PRKAB1 Q9Y478 1/20 0.31
CYP4F2 P78329 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30942623 0.86 TDP1 (0.37) CA2
SCHEMBL584939 0.82 TNKS2 (0.41) TNKS2FFAR4CA2CYP11B1CYP11B2
SCHEMBL21357521 0.80 TNKS2 (0.48) TNKS2FFAR4CA2
SCHEMBL38659514 0.78 TNKS2 (0.39) TNKS2FFAR4CA2CYP4A11LTA4H
SCHEMBL584236 0.78 TNKS2 (0.43) TNKS2FFAR4CA2CYP4A11TLR8
SCHEMBL7766006 0.78
SCHEMBL1568422 0.78 IGF1R (0.44) FFAR4CA2CYP11B1CYP11B2TBXA2R
SCHEMBL16953925 0.77 ACHE (0.42) CYP4A11CYP4F2
SCHEMBL13267737 0.75 TNKS2 (0.50) TNKS2CA2TBXA2RCYP4A11LTA4H
SCHEMBL16961664 0.75 EPAS1 (0.39) TNKS2FFAR4CYP11B1CYP11B2TBXA2R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8188082-B2 5,6,7,8-tetrahydro-imidazo[1,5-α]pyrazine derivatives ACTELION PHARMACEUTICALS LTD. (CH) 2012-05-29 US disclosed
EP-2125823-B1 5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2012-02-15 EP disclosed
US-20100093740-A1 5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE DERIVATIVES ACTELION PHARMACEUTICALS LTD. (CH) 2010-04-15 US disclosed
EP-2125823-A1 5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE DERIVATIVES Actelion Pharmaceuticals Ltd. (CH) 2009-12-02 EP disclosed
WO-2008078291-A1 5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2008-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100093740-A1 5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE DERIVATIVES HCRTR1, HCRTR2, NPY5R TNKS2 4817/4885FFAR4 191/4885CA2 672/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.